Our Team


In pursuit of delivering patients the fastest possible visual restoration gene therapy

More than a million patients worldwide with inherited retinal disease are still waiting for an effective treatment that can end their fear of going blind.
Seeing them firsthand, a mission-driven ophthalmologist founded Restore Vision to develop a gene therapy to stop—even reverse—the disease in its tracks.
We can see a future where this too will be a treatable condition. And we want you to see it too.


  • Yusaku Katada, M.D., Ph.D.

    Yusaku Katada, M.D., Ph.D.

    President & CEO
  • Hikaru Miyazaki

    Hikaru Miyazaki

    Executive Vice President & COO
  • Naoyuki Nakada, Ph.D.

    Naoyuki Nakada, Ph.D.

    SVP, Preclinical Lead


  • Katsuyuki Nagai, Ph.D.

    Katsuyuki Nagai, Ph.D.

    CMC advisor
  • Hitoshi Kawamura Ph.D.

    Hitoshi Kawamura Ph.D.

    R&D advisor
  • Shinichi Koizumi, Ph.D.

    Shinichi Koizumi, Ph.D.

    Executive Advisor
  • Tsutomu Uchiyama, Ph.D.

    Tsutomu Uchiyama, Ph.D.

    IP Strategy Advisor
  • Ken Shimokawa, Ph.D.

    Ken Shimokawa, Ph.D.

    Strategic Advisor

About Us

Company Name Restore Vision Inc.
Toranomon Hills Business Tower 15F, 1-17-1 Toranomon, Minato-ku, Tokyo
Kobe Office
Creative Lab for Innovation in Kobe (CLIK) 2F, 6-3-7 Minato-jima Minami-machi, Chuo-ku, Kobe-City, Hyogo
Established November 14, 2016
Representative Yusaku Katada, M.D., Ph.D.
Business Activities Research and development of regenerative medicine